Save time and jump to the most important pieces.
SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)
SC 13G/A - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)
SC 13G - Ampio Pharmaceuticals, Inc. (0001411906) (Subject)
15-12G - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
25 - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
8-K - Ampio Pharmaceuticals, Inc. (0001411906) (Filer)
Roth Capital resumed coverage of Ampio Pharmaceuticals with a rating of Buy and set a new price target of $4.00
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
4 - Ampio Pharmaceuticals, Inc. (0001411906) (Issuer)
ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. Further discussion is included in footnote 2 of the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is
ENGLEWOOD, Colo., March 25, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio") today announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). The Company today notified the NYSE American of its intention to voluntarily delist its shares of common stock from the NYSE American. The Company intends to file a Form 25 with
ENGLEWOOD, Colo., Feb. 14, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company" or "Ampio"), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio's only product development opportunity. Ampio reported that the efficacy results of these studies do not support an Investigational New Drug ("IND") submission which was anticipated in early 2025. Specifically, whereas previous smaller studies had demonstrated that OA-201 showed efficacy versus saline control to reduce p
ENGLEWOOD, Colo., Feb. 10, 2022 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, today announced the appointment of Elizabeth Varki Jobes, Esq. to the Company's Board of Directors. The appointment of Ms. Jobes expands the Company's Board of Directors from seven members to eight. "We welcome Elizabeth as an addition to our Board of Directors as we enter into a pivotal period at Ampio," said Mike Martino, Chairman and CEO of Ampio. "Throughout her impress
ENGLEWOOD, Colo., May 26, 2023 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) (the "Company") today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on June 8, 2023. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on June 8, 2023. Shares of Series D Preferred Stock will be uncertificated and represented in book-entry form.
ENGLEWOOD, Colo., April 27, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, announced that the Company will be hosting a conference call on April 28, 2022 at 8am EDT regarding the update from the Food and Drug Administration with respect to its AP-013 study. Conference Call Details Date/Time: April 28, 2022 at 8am EDT Title: Investor Update Call - FDA Response Letter AP-01
ENGLEWOOD, Colo., March 23, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the Company will be hosting its fourth quarter earnings and business update call March 29 at 4:30pm EST. Conference Call Details Date/Time: March 29, 2022, at 4:30 pm EST Conferencing Link: https://event.on24.com/wcc/r/3683372/9CD2C8B658E56541C487F44C34E897BBAccess Code: 66744 Canada dial-in number (Toll Free): 1 833 950 0062 Canad